Dr Reddy’s Lab out of Remdesivir stock

‘Ramping up production, reduced MRP by 50% so that price is not a barrier’

Drugmaker Dr. Reddy’s Laboratories has said that it has run out of stock of Remdesivir, the anti-viral injection used in the treatment of COVID- and whose demand has surged in the face of a deadlier second wave of the pandemic sweeping the country. “Currently we are out of stock for Remdesivir. We will regularly update the website (https://www.readytofightcovid.in/) as we get new batches of stocks,” the company tweeted on Thursday night. It followed a release on April 14 in which the company said it was “making every effort to ensure Remdesivir [which it sells] under the brand name Redyx reaches as many patients in India, as possible”. “We are ramping up production... also reduced MRP by 50% so that price is not a barrier to access,” it had said. Market situation on supplies is expected to ease in the next few weeks, said Dr.Reddy’s, which has set up the website to update real-time city-wise availability of Redyx at stockists and hospitals.